This website is intended for New Zealand patients prescribed Lagevrio® (molnupiravir) and their carers.
RESTRICTED MEDICINE (PHARMACIST ONLY MEDICINE)
KEEP OUT OF REACH OF CHILDREN
Each capsule contains 200 mg molnupiravir
Each bottle contains 40 capsules
TT50-10988
Store below 30ºC
If you have any questions about your condition or the medicine you have been prescribed, please talk to your doctor or pharmacist.
The information provided on this website should be discussed with a healthcare professional and does not replace their advice.
Have a question about an MSD Product or want to report an Adverse Event or Quality Issue?
Phone: 0800 500 673
Monday – Friday 9:30 a.m. – 5:30 p.m. Australian Eastern Daylight Time
Email: dpoc.australia@msd.com
MSD New Zealand Address
Merck Sharp & Dohme (New Zealand) Limited. Level 3, 123 Carlton Gore Road, Newmarket, Auckland
Lagevrio® (molnupiravir) is available for eligible patients with COVID-19 following a consultation with a doctor or pharmacist. Lagevrio is used to treat mild to moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalisation.
Lagevrio is not recommended in pregnancy. Discuss the need for a pregnancy test with your doctor or pharmacist if you are of childbearing potential and sexually active. If you can become pregnant, you should use effective birth control while you are taking Lagevrio and for 4 days after the last dose of Lagevrio. If you are a male who is sexually active with a partner who could become pregnant, use a reliable method of contraception during treatment and for 3 months after the last dose of Lagevrio. Breastfeeding is not recommended during treatment and for 4 days after the last dose of Lagevrio.
Do not take Lagevrio if you are allergic to molnupiravir or any of the other ingredients. Allergic reactions can happen in people taking Lagevrio. Stop taking Lagevrio and call your doctor right away if you get any of these symptoms: hives, rapid heartbeat, trouble swallowing or breathing, swelling of the mouth, lips, or face, throat tightness, hoarseness, skin rash. The most common side effects of Lagevrio are diarrhoea, nausea, and dizziness. Based on Consumer Medicine Information (CMI) dated 13 September 2023.
Please read the Lagevrio CMI for more information, available at www.medsafe.govt.nz.
If you test positive for COVID-19, talk to your doctor or pharmacist to see if Lagevrio is right for you. Always read the label. Use only as directed. If symptoms continue or you have side effects, see your healthcare professional.
Lagevrio is free of charge for certain patients with COVID-19 – restrictions apply.
Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
NZ-LAG-00103 First issued November 2023 TAPS DA MR8540.